(secondQuint)Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab.

 Study involves dose escalation phase (completed in Nov-2016) to find the RP2D dose and an expansion phase to assess the safety and tolerability of the RP2D dose within stage III b/IV NSCLC and relapsed/refractory gastric adenocarcinoma subjects.

 Plan is to include approximately 51 HA-high subjects (30 NSCLC and 21 GAC subjects) in the dose expansion phase on the obtained RP2D from dose escalation phase of the study.

.

 Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab@highlight

This is a phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) subjects with relapsed/refractory Non-Small Cell Lung Cancer (NSCLC) and HA-high subjects with relapsed/refractory gastric adenocarcinoma.

